Navamedic

Navamedic's mission is to be a reliable supplier of high-quality pharmaceutical products and medical nutrition, focusing on niche therapeutic areas with unmet needs. The company has achieved consistent growth, reporting 2025 revenue of MNOK 565.4 and a profitable EBITDA of MNOK 47.6, supported by a portfolio of ~50 brands. Its strategy centers on a capital-efficient, commercial-stage model: in-licensing or acquiring approved or near-approved products, then leveraging its established Nordic regulatory, distribution, and market access expertise for launch and lifecycle management. A key strategic pillar is building deep patient community relationships, exemplified by its 'In Good Company' support program for metabolic diseases.

Navamedic's platform is its integrated commercial expertise in the Nordic pharmaceutical market, encompassing regulatory knowledge, distribution networks, and a patient-centric commercialization model exemplified by its 'In Good Company' support programs.

Navamedic competes with large pharma companies in broader categories, regional specialty pharma firms, and medical nutrition specialists. Its primary advantages are local Nordic agility, deep patient community integration through support programs, and a highly efficient, lean operational cost structure.